{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-037652","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.430127+00:00","generated_at":"2026-06-04T06:04:16.121539+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CV Sciences FY2023 revenue $16.0M (flat), gross margin improves to 44.3% from 34.2%","bullets":["Revenue $16.0M for FY2023, flat vs $16.2M in 2022; Q4 revenue $3.8M down 2% YoY.","Gross margin 44.3% (FY2022: 34.2%); operating income $3.4M vs loss $6.8M, helped by $6.2M payroll tax reversal.","Cash $1.3M at year-end; cash from operations $2.3M including $2.5M employee retention credit.","Adjusted EBITDA negative $2.3M in FY2023, improved from negative $6.1M in FY2022.","Acquired Cultured Foods in Q4 2023; launched new products; #1 hemp extract brand in natural retail per SPINS."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-037652","json":"https://secwatch.observer/filing/0000950170-24-037652.json","markdown":"https://secwatch.observer/filing/0000950170-24-037652.md","text":"https://secwatch.observer/filing/0000950170-24-037652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024037652/0000950170-24-037652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024037652/cvsi-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:04:16.121539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a12fc380aacf3fba927d6b92849e07d82b0dd50","claim":"CV Sciences, Inc. reported the fourth quarter of 2023 results: revenue $3.8 million.","evidence_excerpt":"Revenue of $3.8 million for the fourth quarter 2023 compared to $4.1 million in the third quarter 2023;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024037652/0000950170-24-037652-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Revenue","value":"$3.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"47250c1c75c73044bcfa2deb111dd179fcf8402e","claim":"CV Sciences, Inc. reported fiscal year ended December 31, 2023 results: revenue $16.0 million.","evidence_excerpt":"Generated revenue of $16.0 million for fiscal 2023 compared to $16.2 million for 2022;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024037652/0000950170-24-037652-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$16.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}